| abstract |
Compounds of the formula (I): R1-CO-N(OH)-CR?2R3-CR4R5¿-CONH-CR?6R7-CONR8R9¿, wherein R1 is C¿1-6?alkyl, aryl or aryl C1-6alkyl; R?2¿ is hydrogen, C¿1-6?alkyl, C3-8cycloalkyl, aryl or arylC1-6alkyl; R?3¿ is hydrogen, C¿1-6?alkyl or arylC1-6alkyl; or R?2 and R3¿; together with the carbon atom to which they are joined, form a C¿3-8?cycloalkyl ring; R?4¿ is hydrogen, C¿1-6?alkyl or aryl C1-6alkyl; R?5¿ is hydrogen, C¿1-6?alkyl or arylC1-6alkyl; R?6¿ is hydrogen, C¿1-6?alkyl, C2-6alkenyl, C3-8cycloalkylC1-6alkyl, arylC1-6alkyl, heteroarylC1-6alkyl or the side-chain of a naturally occuring amino acid; R?7¿ is hydrogen or C¿1-6?alkyl; R?8¿ is hydrogen, C¿1-6?alkyl, C3-8cycloalkyl, C3-8cycloalkenyl, arylC1-6alkyl, heteroarylC1-6alkyl or heterocyclyC1-6alkyl; R?9¿ is hydrogen or C¿1-6?alkyl; or R?8 and R9¿, together with the nitrogen atom to which they are joined, form a heterocyclic ring; wherein any group or ring in R1-R9 is optionally substituted; and pharmaceutically-acceptable salts and in vivo hydrolysable precursors thereof, are inhibitors of one or more metalloproteinase enzymes and therefore are useful in treating various disease conditions including inflammatory and allergic diseases. |